Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Part of paid clinical trials in San Francisco, California.

Sponsor
Thomas Hope
Study ID
NCT06474533
Status
Recruiting
Apply to this trial

Conditions

  • Intracranial Neoplasm

Eligibility Criteria

Sex
ALL
Age
4 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fluorethyltyrosine (18-F) — DRUG
    Given intravenously (IV)
  • Positron Emission Tomography (PET) — PROCEDURE
    Undergo Imaging Procedure

Study Details

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Key Dates

Start date
Jun 21, 2024
Status verified
Mar 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
199 participants (estimated)

Arms

  • Arm: Population 1: Participants with intracranial neoplasms
    Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging.
  • Arm: Population 2: Participants with suspected glial neoplasms
    Participants with suspected glial neoplasms (Grade 2 - 4) planning to undergo biopsy or surgery prior to non-investigational, standard-of-care, primary treatment (radiation therapy and/or surgery)

Primary Outcome Measure

Maximum Intracranial lesion tumor-to-background ratio (TBRmax) [ Time Frame: Up to 3 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Louise Magat
[email protected]
415-502-1822
[email protected]
(887) 827-3222
Javier Villanueva-Meyer, MD (PRINCIPAL_INVESTIGATOR)
Thomas Hope, MD (SUB_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies